73746-44-8

Usage

Uses

Used in Pharmaceutical Research:
4,5-Diiodo-2-methyl-1H-imidazole is used as a research compound for its potential medicinal properties, including antimicrobial and antifungal activities. It is studied for its effectiveness in treating various medical conditions, making it a promising candidate for drug development.
Used in Organic Synthesis:
In the field of organic synthesis, 4,5-Diiodo-2-methyl-1H-imidazole is utilized as a reagent, particularly in the preparation of other imidazole derivatives. Its versatile reactivity allows for the creation of a wide range of chemical compounds, contributing to the advancement of chemical research and development.
Used in Antimicrobial Applications:
4,5-Diiodo-2-methyl-1H-imidazole is employed as an antimicrobial agent, demonstrating effectiveness against various types of bacteria. Its ability to inhibit bacterial growth makes it a valuable component in the development of new antimicrobial drugs and treatments.
Used in Antifungal Applications:
This chemical compound is also used as an antifungal agent, showing potential in combating fungal infections. Its antifungal properties are currently being investigated for use in medical treatments and pharmaceutical formulations to address fungal-related health issues.

InChI:InChI=1/C4H4I2N2/c1-2-7-3(5)4(6)8-2/h1H3,(H,7,8)

Upstream product

• 693-98-1 2-methylimidazole 

Downstream Products

• 73746-45-9 4⁽⁵⁾-iodo-2-methyl-1H-imidazole 
• 73746-45-9 4-iodo-2-methyl-1H-imidazole 
• 13369-82-9 4,5-diiodo-1,2-dimethylimidazole 

Relevant academic research and scientific papers

FLEXIBLE PIEZOELECTRIC AND FERROELECTRIC HALOIMIDAZOLE CRYSTALS

Provided herein are substituted haloimidazole crystals, the substituted haloimidazole crystal comprising a substituted haloimidazole compound wherein the substituents are selected from the group consisting of hydrogen, an alkyl, and a halogen. The substituted haloimidazole crystals may further comprise second substituted haloimidazole. The substituted haloimidazole crystals may be piezoelectric, ferroelectric, flexible, or any combination thereof. Also provided herein are methods for preparing substituted haloimidazole crystals.

New approach to electrochemical iodination of arenes exemplified by the synthesis of 4-iodopyrazoles of different structures

The two-stage electrosynthesis of 4-iodosubstituted pyrazole derivatives was performed. At the first stage, KIO3 was obtained at the Ni anode under the undivided galvanostatic conditions of electrolysis of an aqueous alkaline solution of KI (or I2) at the Ni anode. At the second stage, pyrazole and its derivatives were iodinated in the heterophase (H2O-CHCl3 (CCl4)) medium by the KIO3-KI (or KIO3-I2) system in the presence of H2SO4. The yields of iodopyrazoles were 74-92%. The electrochemical iodination of anisole, 2-methylpyrazole, and thiophene was carried out to form 4-iodoanisole (88% yield), 4,5-diiodo-2-methylimidazole (54% yield), and a mixture of 2-iodothiophene (60% yield) and 2,5-diiodothiophene (4% yield).

Synthesis, crystal structure and antibacterial activity of new highly functionalized ionic compounds based on the imidazole nucleus

Several new highly functionalized imidazolium derivatives were synthesized, via appropriate synthetic routes, using imidazole, 1-methylimidazole and 2-phenyl-1-methylimidazole as key intermediates. The antibacterial activity of the prepared compounds was evaluated against: Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella thipymurium using disk-diffusion and MIC methods. Crystal X-ray structures are reported for six compounds.

Ionic liquid iodinating reagent for mild and efficient iodination of aromatic and heteroaromatic amines and terminal alkynes

Hexamethylene bis(N-methylimidazolium) bis(dichloroiodate) (HMBMIBDCI), an ionic liquid iodinating reagent, have been prepared and characterized. Its ability to perform iodination reactions with a variety of substrates has been explored. In general, iodination reactions of aromatic and heteroaromatic amines proceed with good yields in the absence of solvent. Reactions of terminal alkynes in the presence of 1,8-diazabicyclo [5.4.O] undec-7-ene and tetrahydrofuran have been investigated as well.

Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1

A novel series of non-peptidic OX1R/OX2R orexin receptor antagonists was prepared by heterocyclic replacement of the dimethoxyphenyl moiety contained in the tetrahydroisoquinoline core skeleton of almorexant. Introduction of substituted imidazole moieties delivered potent dual orexin receptor antagonists with nanomolar potency for hOX1R and hOX2R suitable for further fine-tuning. The preparation of these novel orexin receptor antagonists and the outcome of preliminary structure-activity relationship studies are described in this communication.

A simple method for iodination of heterocyclic compounds using HIO 4/NaCl/silica gel/H2SO4 in water

A fast and simple method for iodination of some heterocycles is reported. The reactions were carried out in water, using HIO4/H 2SO4/NaCl/silica gel at moderate temperatures of 25-50 °C. Springer-Verlag 2011.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

Direct synthesis of pyrroles via a silver-promoted three-component reaction involving unusual imidazole ring opening

A novel silver-promoted three-component reaction toward the synthesis of multifunctionalized pyrroles has been developed. This reaction involves an unusual imidazole ring decomposition, presumably via 1,5-isomerization and subsequent hydrolysis.

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity

We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-